Q-omics provides the consensus-scored CHIA profile across patient tissues and cancer cell-line models. CHIA expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CHIA is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, CHIA RNA expression shows 12,871 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, LUSC, and LSCC as cancer lineages where CHIA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHIA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHIA survival associations across molecular data types. CHIA RNA expression shows survival associations in the most cancer types (16), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHIA RNA expression–survival associations across cancer types. High CHIA expression shows unfavorable associations in KIRP, LUSC and MESO, but favorable associations in LUAD, HNSC and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CHIA RNA expression.
This table summarizes CHIA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CHIA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHIA shows lower tumor expression in LUSC, LUAD, STAD, KIRC and PRAD and higher tumor expression in COAD. The LUSC box plot shows higher CHIA RNA expression in normal versus tumor tissue (log2 FC = −3.129, t-test p < 0.001).
This table shows molecular features associated with CHIA in patient tissues and cancer cell lines. In patient samples, CHIA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHIA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
